A Tandem Oxidative Annulation Strategy for the Synthesis of

Tetracyclic 3-Spirooxindole Benzofuranones

Chunxia Zhang,⁺Min Liu,⁺ Mingruo Ding, Hao Xie and Fengzhi Zhang^{*}

College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region Zhejiang University of Technology, Hangzhou, 310014, P. R. China

Supporting Information

Table of contents:

1. General information:	S3
2. General procedures for synthesizing raw materials:	S4
3. Synthesis and characterization of raw materials:	S7
4. Conditions optimization of 3-spirooxindole benzofuranone:	S177
5. General procedure for the oxidative annulation:	S19
6. Synthesis and characterization of the 3-spirooxindole benzofuranone:	S20
7. The data of crystal:	\$322

⁺These authors contributed equally to this work.

^{*} Corresponding author, zhangfengzhi@zjut.edu.cn

8. Experiments about mechanistic studies:	
9. References:	
10. NMR spectra:	S16

1. General information:

All reagents were obtained from commercial suppliers and used without further purification. The benzoic acid starting materials were prepared according to the know procedure.^{1,2} Yields for all compounds were determined by the column chromatography which was generally performed on silica gel (200-300 mesh) using petroleum ether 40-60 (PE)/EtOAc as eluent, and reactions were monitored by thin layer chromatography (TLC) on a glass pate coated with silica gel with fluorescent indicator (GF254) using UV light. The ¹H reree and ¹³C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker ADNANCE III 500 MHz using CDCl₃ as solvent with TMS as internal standard. Chemical shifts are given in ppm (δ) referenced to CDCl₃ with 7.28 for ¹H and 77.03 for ¹³C, and to DMSO-*d*₆ with 2.50 for ¹H and 39.52 for ¹³C. Signals are abbreviated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet, and coupling constants are expressed in hertz. Melting points were measured on a SGW_® X-4B apparatus and uncorrected. HRMS were recorded on Agilent 6210TOF LC/MS mass spectrometer.





General procedure A:

The benzoic acid starting materials were prepared according to the know procedure¹ and the preparation of **13a** was used here as an example.

To a solution of phenyl hydrazine (1.1 g, 10 mmol) and 1-indanone (1.3 g, 10 mmol) in ethanol (7 mL) was added glacial acetic acid (50 μ L). The resulting mixture was stirred at reflux for 15 minutes before it was cooled to room temperature. Upon cooling, long and white crystals precipitated out of

solution, which were collected via vacuum filtration and combined with isopropanol (34 mL). Sulfuric acid (36 N, 1.2 mL) was added via syringe and the resulting solution was stirred at reflux (90 °C) for 16 hours. Upon cooling to room temperature, the solution was basified to pH 10 with aqueous sodium hydroxide (2% NaOH by mass) resulting in the formation of precipitate. The solid was collected by vacuum filtration to yield **S1a** in 50% yield (1.0 g, 5 mmol).

To a solution of **S1a** (1.0 g, 5 mmol) in toluene (6.7 mL) was added aqueous sodium hydroxide (50% NaOH by mass, 2.7 mL), TBAF (130 mg, 1.34 mmol), and iodomethane (2.0 mL, 32 mmol). The reaction mixture was stirred vigorously at 40 °C for 17 hours and then at 55 °C for an additional 1.5 hours. Upon cooling to room temperature, the mixture was diluted with toluene (5 mL) and H₂O (5 mL), and the aqueous layer was extracted ethyl acetate (2 x 5 mL). Organic layers were combined, dried over anhydrous magnesium sulfate and concentrated *in vacuo*. Crude product was purified by flash column chromatography (PE/EtOAc = 50:1) to give **S2a** (0.9 g, 85%) as pale brown solid.

To a solution of **S2a** (0.9 mg, 4.2 mmol) in dichloromethane (108 mL) and saturated aqueous NaHCO₃ (13 mL) at 0 °C was added *m*-CPBA (77%, 2.3 g, 13.3 mmol) portionwise over 5 minutes. The reaction mixture was stirred at 0 °C for 30 minutes and then warmed to room temperature over 40 minutes. The reaction was subsequently quenched via addition of NaOH (1N, 38 mL) and the resulting aqueous layer was extracted dichloromethane (2 X 100 mL) and ethyl acetate (100 mL). Organic layers were combined and washed brine (100 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (PE/EtOAc = 4:1) on silica gel to provide the **S3a** (0.8 g, 87%) as pale brown solid.

To a solution of azocine **S3a** (0.8 g, 3.7 mmol) in ethanol (8.8 mL) was added sodium hydroxide (20% aq., 2.2 mL), and the solution was stirred at room temperature for 0.5 h before neutralising with hydrochloric acid (3 M) and extracting with diethyl ether (3 X 10 mL). The combined organic phase were washed with water (3 X 10 mL) and saturated brine (10 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (DCM/MeOH = 50:1) on silica gel to provide the **13a** (0.8 g, 90%) as a yellow solid.



General procedure B:

The benzoic acid starting materials with ^{*i*}Pr protecting group on nitrogen were prepared according to the know procedure² and the preparation of **13h** was used here as an example.

To a solution of methyl 2-iodobenzoate (4.7 mL, 28.7 mmol) in THF (103 mL) were added 2-TMS-acetylene (3.1 g, 31.3 mmol), PPh₃ (191.5 mg, 0.7 mmol), Pd(PPh₃)₂Cl₂ (1.0 g, 1.5 mmol), and Et₃N (24.0 mL, 172.4 mmol). The reaction mixture was degassed and stirred under an atmosphere of nitrogen for 20 min before the addition of CuI (116.3 mg, 0.6 mmol). The reaction was then stirred at rt for 12 h, after which time additional Pd(PPh₃)₂Cl₂ (205.0 mg, 0.29 mmol) and CuI (27.4 mg, 0.14 mmol) were added and stirring continued for 6 h. The reaction mixture was diluted with diethyl ether (140 mL) and then washed with HCl solution (0.1 M, 2 X 140 mL), H₂O (140 mL), and brine (140 mL). The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. The

residue was purified by column chromatography (PE/EtOAc = 25:1) on silica gel to provide the S4a (5.9 g, 89%) as a pale yellow oil.

To a solution of compound **S4a** (1.7 g, 7.5 mmol) in THF (97 mL) were added 4-fluoro-2-iodoaniline (2.0 g, 8.3 mmol), PPh₃ (0.4 g, 1.5 mmol), Pd(PPh₃)₂Cl₂ (0.5 g, 0.8 mmol), and piperidine (10.8 mL, 109 mmol). The reaction mixture was degassed and stirred under an atmosphere of nitrogen for 20 min before the addition of CuI (0.3 g, 1.5 mmol) and K₂CO₃ (1.2 g, 10.0 mmol). The reaction mixture was stirred at reflux, MeOH (9.7 mL) was added dropwise, and heating was continued for 12 h. Additional Pd(PPh₃)₂Cl₂ (52.2 mg, 0.1 mmol) and CuI (30 mg, 0.2 mmol) were then added, and stirring was continued for 6 h at reflux. The reaction mixture was cooled to rt, diluted with ethyl acetate (500 mL), and then washed with HCl solution (0.1 M, 2 X 100 mL), H₂O (100 mL), and brine (100 mL). The organic layer was dried (Na₂SO₄) and concentrated *in vacuo*. The residue was purified by column chromatography (PE/EtOAc = 6:1) on silica gel to provide **S5a** (1.4 g, 70%) as a yellow solid.

To a solution of alkyne **S5a** (1.4 g, 5.2 mmol) in trifluoroacetic acid (26 mL) was added $Cu(OTf)_2$ (37.6 mg, 0.1 mol). The solution was stirred at reflux for 5 h before it was cooled to room temperature. Trifluoroacetic acid was evaporated under reduced pressure. The residue was partitioned between CH_2Cl_2 (260 mL) and water (260 mL). The organic layer was further washed with brine (2 x 260 mL), dried (Na₂SO₄), and concentrated *in vacuo*. The residue was purified by column chromatography (PE/EtOAc = 5:1) on silica gel to provide the **S6a** (1.1 g, 81%) as a yellow solid.

To a solution of **S4a** (164.1 mg, 0.6 mmol), 2-propanone (27.2 mg, 0.9 mmol) and CF₃COOH (228 mg, 2 mmol) in DMF (2 mL). The solution was stirred at room temperature for 2 h. The reaction was added STAB (212 mg, 0.10 mmol) and stirred at 50 °C for 12 h. The reaction mixture was then cooled to rt and diluted with water (5 mL) before it was extracted with EtOAc (3 X 10 mL). The combined organic phase were washed with saturated brine (10 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (DCM/MeOH = 50:1) on silica gel to provide the **13h** (44.4 mg, 24%) as a yellow solid.

3. Synthesis and characterization of raw materials:



2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13a):

Following the general procedure A, **13a** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.8 g, 90% yield); Mp = 179-180 °C; R_f = 0.20 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, CDCl₃) δ 8.69 (s, 1 H), 8.11 (d, *J* = 7.7 Hz, 1 H), 7.94 (d, *J* = 7.7 Hz, 1 H), 7.53 (t, *J* = 7.2 Hz, 1 H), 7.41 (dt, *J* = 14.7, 7.4 Hz, 2 H), 7.24 (d, *J* = 7.5 Hz, 1 H), 6.71 (d, *J* = 8.6 Hz, 1 H), 6.65 (t, *J* = 7.5 Hz, 1 H), 4.75 (s, 2 H), 2.85 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 199.6, 171.6, 151.8, 138.0, 135.1, 133.0, 132.5, 131.7, 129.3, 127.2, 117.3, 114.4, 111.8, 44.9, 29.5 ppm.



2-(2-(4-methyl-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13b):

Following the general procedure A, **13b** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.8 g, 87% yield); Mp = 161-162 °C; R_f = 0.23 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.70 (s, 1 H), 8.54 (q, J = 4.8 Hz, 1 H), 7.95–7.89 (m, 2 H), 7.51 (td, J = 7.5, 1.4 Hz, 1 H), 7.38 (td, J = 7.6, 1.2 Hz, 1 H), 7.31–7.28 (m, 1 H), 6.54 (s, 1 H), 6.47 (dd, J = 8.2, 1.2 Hz, 1 H), 4.72 (s, 2 H), 2.80 (d, J = 5.0 Hz, 3 H), 2.31 (s, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 199.0, 168.8, 151.9, 145.7, 138.2, 133.1, 132.3, 132.1, 131.5, 130.7, 127.1, 115.7, 115.3, 111.6, 45.0, 29.4, 22.3 ppm.



2-(2-(4,5-dimethyl-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13c):

Following the general procedure A, 13c was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.5 g, 64% yield); Mp = 161-162 °C; R_f =

0.21 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.69 (s, 1 H), 8.35 (d, J = 5.0 Hz, 1 H), 7.92 (dd, J = 7.8, 1.3 Hz, 1 H), 7.78 (s, 1 H), 7.50 (td, J = 7.5, 1.4 Hz, 1 H), 7.37 (td, J = 7.6, 1.2 Hz, 1 H), 7.29 (d, J = 6.9 Hz, 1 H), 6.56 (s, 1 H), 4.73 (s, 2 H), 2.79 (d, J = 4.8 Hz, 3 H), 2.24 (s, 3 H), 2.18 (s, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 199.0, 168.7, 144.8, 138.0, 133.1, 132.4, 132.2, 131.4, 130.7, 127.1, 45.2, 30.6, 20.7, 18.9 ppm.



2-(2-(5-methoxy-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13d):

Following the general procedure A, **13d** was purified by DCM/MeOH (25:1) and obtained as a yellow solid (0.9 g, 84% yield); Mp = 160-161 °C; R_f = 0.15 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 8.18 (s, 1 H), 7.95 (dd, J = 7.8, 1.3 Hz, 1 H), 7.59 – 7.46 (m, 2 H), 7.38 (td, J = 7.6, 1.2 Hz, 1 H), 7.34–7.27 (m, 1 H), 7.16 (dd, J = 9.1, 2.9 Hz, 1 H), 6.71 (d, J = 9.2 Hz, 1 H), 4.77 (s, 2 H), 3.76 (s, 3 H), 2.78 (s, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 198.9, 168.3, 148.3, 146.6, 137.6, 132.6, 131.7, 131.0, 130.3, 126.7, 123.4, 116.5, 114.8, 112.5, 55.8, 44.9, 29.3 ppm.



2-(2-(methylamino)-5-(trifluoromethyl)phenyl)-2-oxoethyl)benzoic acid (13e):

Following the general procedure A, **13e** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (1.0 g, 89% yield); Mp = 203-204 °C; $R_f = 0.23$ (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.74 (s, 1 H), 8.89 (q, J = 4.7 Hz, 1 H), 8.29 (d, J = 1.2 Hz, 1 H), 7.96 (dd, J = 7.8, 1.3 Hz, 1

H), 7.70 (dd, J = 9.0, 1.9 Hz, 1 H), 7.54 (td, J = 7.5, 1.4 Hz, 1 H), 7.40 (td, J = 7.6, 1.2 Hz, 1 H), 7.36–7.30 (m, 1 H), 6.90 (d, J = 9.0 Hz, 1 H), 4.81 (s, 2 H), 2.87 (d, J = 5.0 Hz, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ 199.6 (s), 168.6 (s), 153.6 (s), 137.8 (s), 133.3 (s), 132.3 (s), 131.2 (s), 130.9 (d, J = 16.6 Hz), 129.4 (s), 127.3 (s), 126.4 (s), 124.3 (s), 116.5 (s), 114.1 (d, J = 32.7 Hz), 112.6 (s), 45.2 (s), 29.6 (s) ppm.



2-(2-(5-fluoro-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13f):

Following the general procedure A, **13f** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.9 g, 92% yield); Mp = 191-192 °C; R_f = 0.22 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.71 (s, 1 H), 8.35 (d, J = 4.9 Hz, 1 H), 7.95 (dd, J = 7.8, 1.3 Hz, 1 H), 7.88 (dd, J = 10.4, 3.0 Hz, 1 H), 7.53 (td, J = 7.5, 1.4 Hz, 1 H), 7.46–7.25 (m, 3 H), 6.74 (dd, J = 9.4, 4.6 Hz, 1 H), 4.74 (s, 2 H), 2.80 (d, J = 4.8 Hz, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ 199.2 (d, J = 2.8 Hz), 168.7 (s), 152.3 (d, J = 230.4 Hz), 148.7 (s), 137.9 (s), 133.2 (s), 131.2 (s), 130.8 (s), 127.3 (s), 123.0 (d, J = 22.9 Hz), 117.0 (d, J = 22.1 Hz), 116.7 (d, J = 5.5 Hz), 113.1 (d, J = 7.1 Hz), 45.4 (s), 29.8 (s) ppm.



2-(2-(5-chloro-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13g):

Following the general procedure A, **13g** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.8 g, 82% yield); Mp = 191-192 °C; $R_f = 0.22$ (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.72 (s, 1 H), 8.50 (d, J = 4.2 Hz, 1 H), 8.04 (d, J = 2.5 Hz, 1 H), 7.95 (dd, J = 7.8, 1.3 Hz, 1

H), 7.53 (td, J = 7.5, 1.4 Hz, 1 H), 7.45 (dd, J = 9.1, 2.5 Hz, 1 H), 7.39 (td, J = 7.6, 1.2 Hz, 1 H), 7.36–7.28 (m, 1 H), 6.77 (d, J = 9.2 Hz, 1 H), 4.75 (s, 2 H), 2.80 (d, J = 3.7 Hz, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) $\delta = 199.1$, 168.6, 150.4, 137.9, 134.9, 133.2, 132.3, 131.2, 131.0, 130.8, 127.3, 118.1, 117.6, 113.8, 45.3, 29.6 ppm.



2-(2-(5-fluoro-2-(isopropylamino)phenyl)-2-oxoethyl)benzoic acid (13h):

Following the general procedure B, **13h** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (44.4 mg, 24% yield); Mp = 150-151 °C; R_f = 0.21 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, CDCl₃) δ 12.71 (s, 1 H), 8.42 (d, *J* = 7.1 Hz, 1 H), 7.94 (dd, *J* = 7.8, 1.3 Hz, 1 H), 7.87 (dd, *J* = 10.4, 3.0 Hz, 1 H), 7.52 (td, *J* = 7.5, 1.4 Hz, 1 H), 7.39 (td, *J* = 7.6, 1.2 Hz, 1 H), 7.32 (ddd, *J* = 14.3, 10.6, 5.4 Hz, 2 H), 6.82 (dd, *J* = 9.5, 4.6 Hz, 1 H), 4.72 (s, 2 H), 3.71 (dd, *J* = 12.5, 6.3 Hz, 1 H), 1.14 (d, *J* = 6.3 Hz, 6 H) ppm; ¹³C NMR (126 MHz, DMSO-*d*₆) δ 199.0 (s), 168.2 (s), 151.6 (d, *J* = 230.4 Hz), 146.7 (s), 137.4 (s), 132.8 (s), 131.8 (s), 130.4 (s), 126.8 (s), 122.7 (d, *J* = 23.0 Hz), 116.8 (d, *J* = 21.9 Hz), 115.8 (d, *J* = 5.4 Hz), 113.6 (d, *J* = 6.9 Hz), 44.9 (s), 42.7 (s), 22.4 (s) ppm.



2-(2-(5-chloro-2-(isopropylamino)phenyl)-2-oxoethyl)benzoic acid (13i):

Following the general procedure B, **13i** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (50.4 mg, 25% yield); Mp = 158.7-159.7 °C; R_f = 0.22 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, CDCl₃) δ 12.72 (s, 1 H), 8.59 (d, *J* = 7.5 Hz, 1 H), 8.05 (d, *J* = 2.5 Hz, 1 H), 7.94 (dd, *J* = 7.8, 1.3 Hz, 1 H), 7.52 (td, *J* = 7.5, 1.4 Hz, 1 H), 7.46–7.34 (m, 2 H), 7.30 (d, *J* = 7.5 Hz, 1 H), 6.84 (t, *J* = 10.4 Hz, 1 H), 4.74 (s, 2 H), 3.72 (dp, *J* = 12.8, 6.4 Hz, 1 H), 1.15 (t, *J* = 5.4 Hz, 6 H) ppm; ¹³C NMR (126 MHz, DMSO-*d*₆) δ = 199.0, 168.2, 148.3, 137.4, 134.5, 132.9, 131.9, 130.9, 130.6, 130.4, 126.8, 117.2, 117.0, 114.2, 44.8, 42.7, 22.4 ppm.



2-(2-(2-(benzylamino)phenyl)-2-oxoethyl)benzoic acid (13j):

Following the general procedure A, **13j** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.6 g, 78% yield); Mp = 200-201 °C; R_f = 0.22 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, CDCl₃) δ 8.13 (dd, J = 7.8, 1.2 Hz, 1 H), 7.99 (dd, J = 8.1, 1.3 Hz, 1 H), 7.56 (td, J = 7.5, 1.4 Hz, 1 H), 7.44–7.38 (m, 1 H), 7.37–7.33 (m, 1 H), 7.32–7.21 (m, 7 H), 6.71 (dd, J = 16.2, 8.1 Hz, 2 H), 4.77 (s, 2 H), 4.41 (s, 2 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 200.1, 168.7, 150.7, 139.5, 138.0, 135.2, 133.2, 132.4, 132.2, 131.3, 130.8, 129.0, 127.6, 127.4, 127.2, 117.6, 114.8, 112.5, 46.3, 45.3 ppm.



2-(2-(2-(isopropylamino)-5-methylphenyl)-2-oxoethyl)benzoic acid (13k):

Following the general procedure B, **13k** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (80.1 mg, 43% yield); Mp = 171.8-172.8 °C; $R_f = 0.19$ (DCM/MeOH = 50:1); ¹H NMR (500 MHz, CDCl₃) δ 12.69 (s, 1 H), 8.43 (d, J = 7.5 Hz, 1 H), 7.93 (dd, J = 7.8, 1.1 Hz, 1 H), 7.84 (s, 1 H), 7.51 (td, J = 7.5, 1.3 Hz, 1 H), 7.37 (dd, J = 10.9, 4.3 Hz, 1 H), 7.29 (d, J = 7.3 Hz, 1 H), 7.24 (dd, J = 8.6, 1.6 Hz, 1 H), 6.72 (d, J = 8.7 Hz, 1 H), 4.75 (s, 2 H), 3.69 (dd, J = 13.0, 6.5 Hz, 1 H), 2.24 (s, 3 H), 1.13 (d, J = 6.3 Hz, 6 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) $\delta = 199.3$, 168.7, 147.8, 137.7, 136.0, 132.8, 131.7, 131.6, 130.9, 130.3, 126.7, 121.9, 116.3, 112.2, 44.8, 42.4, 22.6, 19.9 ppm.



5-methyl-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15a):

Following the general procedure A, **15a** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.7 g, 79% yield); Mp = 173.5-174.5 °C; R_f = 0.24 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.65 (s, 1 H), 8.53 (s, 1 H), 8.03 (d, J = 7.7 Hz, 1 H), 7.76 (s, 1 H), 7.43 (t, J = 7.4 Hz, 1 H), 7.32 (d, J = 7.3 Hz, 1 H), 7.18 (d, J = 7.4 Hz, 1 H), 6.73 (d, J = 8.4 Hz, 1 H), 6.64 (t, J = 7.2 Hz, 1 H), 4.70 (s, 2 H), 2.80 (d, J = 3.6 Hz, 3 H), 2.35 (s, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 199.9, 168.8, 151.7, 136.3, 135.3, 135.1, 133.1, 132.8, 132.2, 131.3, 131.1, 117.4, 114.3, 111.7, 44.8, 29.5, 20.9 ppm.



4-methoxy-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15b):

Following the general procedure A, **15b** was purified by DCM/MeOH (25:1) and obtained as a yellow solid (0.8 g, 78% yield); Mp = 194.5-195.5 °C; R_f = 0.14 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.41 (s, 1 H), 8.52 (d, J = 5.0 Hz, 1 H), 8.02 (dd, J = 8.1, 1.4 Hz, 1 H), 7.94 (d, J = 8.7 Hz, 1 H), 7.45–7.37 (m, 1 H), 6.92 (dd, J = 8.7, 2.7 Hz, 1 H), 6.89 (d, J = 2.6 Hz, 1 H), 6.73 (d, J = 8.1 Hz, 1 H), 6.68–6.60 (m, 1 H), 4.75 (s, 2 H), 3.81 (s, 3 H), 2.80 (d, J = 5.0 Hz, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 199.7, 168.2, 162.2, 151.7, 140.9, 135.2, 133.2, 132.2, 123.3, 118.7, 117.4, 114.2, 112.1, 111.6, 55.8, 45.5, 29.4 ppm.



5-fluoro-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15c):

Following the general procedure A, **15c** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.9 g, 89% yield); Mp = 182-183 °C; R_f = 0.22 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 13.02 (s, 1 H), 8.51 (d, J = 4.9 Hz, 1 H), 8.03 (dd, J = 8.1, 1.4 Hz, 1 H), 7.67 (dd, J = 9.7, 2.7 Hz, 1 H), 7.53–7.18 (m, 3 H), 6.74 (d, J = 7.9 Hz, 1 H), 6.69–6.61 (m, 1 H), 4.76 (s, 2 H), 2.80 (d, J = 4.8 Hz, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ 199.0 (s), 167.1 (d, J = 2.5 Hz), 160.6 (d, J = 243.2 Hz), 151.3 (s), 134.9 (s), 134.7 (d, J = 7.6 Hz), 133.8 (d, J = 3.1 Hz), 132.9 (d, J = 6.9 Hz), 131.7 (s), 118.5 (d, J = 20.7 Hz), 116.8 (s), 116.6 (d, J = 22.9 Hz), 113.8 (s), 111.2 (s), 43.9 (s), 29.0 (s) ppm.



4-chloro-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15d):

Following the general procedure A, **15d** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.8 g, 85% yield); Mp = 192-193 °C; R_f = 0.23 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.92 (s, 1 H), 8.55–8.45 (m, 1 H), 8.01 (dd, J = 8.1, 1.4 Hz, 1 H), 7.97–7.92 (m, 1 H), 7.49–7.41 (m, 3 H), 6.74 (d, J = 8.1 Hz, 1 H), 6.69-6.62 (m, 1 H), 4.78 (s, 2 H), 2.81 (d, J = 4.9 Hz, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 198.7, 167.4, 151.3, 140.3, 136.3, 135.0, 132.4, 132.2, 131.8, 129.9, 126.8, 116.8, 113.9, 111.3, 44.4, 29.0 ppm.



4-bromo-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15e):

Following the general procedure A, **15e** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.8 g, 84% yield); Mp = 192-193 °C; R_f = 0.21 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.94 (s, 1 H), 8.49 (q, J = 4.7 Hz, 1 H), 8.01 (dd, J = 8.1, 1.4 Hz, 1 H), 7.89 – 7.78 (m, 1 H), 7.60 (td, J = 4.4, 2.1 Hz, 2 H), 7.54–7.39 (m, 1 H), 6.74 (d, J = 8.1 Hz, 1 H), 6.70 – 6.59 (m, 1 H), 4.77 (s, 2 H), 2.81 (d, J = 4.9 Hz, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 198.7, 167.5, 151.3, 140.3, 135.2, 134.9, 132.2, 131.7, 130.3, 129.7, 125.3, 116.7, 113.8, 111.2, 44.2, 29.0 ppm.





Following the general procedure A, 15f was purified by DCM/MeOH (25:1) and obtained as a yellow solid (0.5 g, 60% yield); Mp = 162-163 °C; R_f =

0.16 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.66 (s, 1 H), 8.17 (s, 1 H), 7.76 (d, J = 1.2 Hz, 1 H), 7.51 (d, J = 2.9 Hz, 1 H), 7.32 (dd, J = 7.7, 1.3 Hz, 1 H), 7.23–7.06 (m, 2 H), 6.71 (d, J = 9.2 Hz, 1 H), 4.70 (s, 2 H), 3.76 (s, 3 H), 2.78 (s, 3 H), 2.35 (s, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 199.5, 168.9, 148.8, 147.0, 136.3, 135.0, 132.9, 132.8, 131.3, 131.1, 123.8, 117.0, 115.2, 113.0, 56.2, 44.9, 29.8, 20.9 ppm.



2-(2-(5-chloro-2-(methylamino)phenyl)-2-oxoethyl)-5-methylbenzoic acid (15g):

Following the general procedure A, **15g** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.6 g, 61% yield); Mp = 166-167 °C; R_f = 0.23 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 8.51 (d, J = 5.1 Hz, 1 H), 8.03 (d, J = 2.5 Hz, 1 H), 7.75 (d, J = 1.4 Hz, 1 H), 7.43 (dd, J = 9.1, 2.5 Hz, 1 H), 7.29 (dd, J = 7.7, 1.4 Hz, 1 H), 7.15 (d, J = 7.7 Hz, 1 H), 6.76 (d, J = 9.2 Hz, 1 H), 4.68 (s, 2 H), 2.80 (d, J = 5.0 Hz, 3 H), 2.34 (s, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 199.1, 168.6, 150.0, 135.9, 134.4, 134.2, 132.5, 132.1, 131.2, 130.9, 130.7, 117.8, 117.2, 113.4, 44.5, 29.2, 20.5 ppm.



2-(2-(5-chloro-2-(methylamino)phenyl)-2-oxoethyl)-4-methoxybenzoic acid (15h):

Following the general procedure A, **15h** was purified by DCM/MeOH (25:1) and obtained as a yellow solid (0.6 g, 63% yield); Mp = 182-183 °C; R_f = 0.16 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 8.51 (d, J = 5.0 Hz, 1 H), 8.01 (s, 1 H), 7.95 (d, J = 8.6 Hz, 1 H), 7.43 (dd, J = 9.1, 2.2 Hz, 1 H), 6.89 (d, J = 7.9 Hz, 1 H), 6.83 (s, 1 H), 6.75 (d, J = 9.1 Hz, 1 H), 4.75 (s, 2 H), 3.80 (s, 3 H), 2.79 (d, J = 4.9 Hz, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ

= 199.4, 161.8, 150.3, 140.1, 134.8, 133.2, 131.1, 118.4, 118.3, 117.6, 113.8, 112.0, 55.7, 45.5, 29.6 ppm.



4-chloro-2-(2-(5-chloro-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15i):

Following the general procedure A, **15i** was purified by DCM/MeOH (50:1) and obtained as a yellow solid (0.7 g, 67% yield); Mp = 171-172 °C; R_f = 0.21 (DCM/MeOH = 50:1); ¹H NMR (500 MHz, DMSO- d_6) δ 12.94 (s, 1 H), 8.48 (d, J = 5.0 Hz, 1 H), 8.01 (d, J = 2.5 Hz, 1 H), 7.95 (d, J = 8.3 Hz, 1 H), 7.47 (ddd, J = 5.9, 4.8, 2.4 Hz, 3 H), 6.78 (d, J = 9.2 Hz, 1 H), 4.77 (s, 2 H), 2.80 (d, J = 5.0 Hz, 3 H) ppm; ¹³C NMR (126 MHz, DMSO- d_6) δ = 198.1, 167.3, 149.9, 140.0, 136.3, 134.6, 132.4, 132.2, 130.6, 129.6, 126.8, 117.5, 117.2, 113.5, 44.5, 29.2 ppm.

4. Conditions optimization of 3-spirooxindole benzofuranone:



entry ^a	Pd cat.	catalyst	ligand	base	solvent ^b	yields (%) ^c
1	$Pd(OAc)_2$	$Cu(OAc)_2/Ag_2CO_3$	Phen	Na ₂ CO ₃	DMA	31
2	$Pd(OAc)_2$	$Cu(OAc)_2/Ag_2CO_3$	Phen	t-BuONa	DMA	12
3	$Pd(OAc)_2$	$Cu(OAc)_2/Ag_2CO_3$	Phen	K_3PO_4	DMA	50
4	$Pd(OAc)_2$	$Cu(OAc)_2/Ag_2CO_3$	Phen	Na_2SO_4	DMA	trace
5	$Pd(OAc)_2$	$Cu(OAc)_2/Ag_2CO_3$	Phen	K ₃ PO ₄ / Na ₂ SO ₄	DMA	44
6	$Pd(OAc)_2$	$Cu(OAc)_2/Ag_2CO_3$	Phen	t-BuOK	DMA	10
7	$Pd(OAc)_2$	CuO/Ag ₂ CO ₃	Phen	K_3PO_4	DMA	65
8		CuO/Ag ₂ CO ₃	Phen	K ₃ PO ₄	DMA	64
9		CuO/Ag ₂ CO ₃	Dipyridyl	K ₃ PO ₄	DMA	62
10		CuO/Ag ₂ CO ₃	PPh ₃	K ₃ PO ₄	DMA	46
11		CuO/Ag ₂ CO ₃	BINAP	K ₃ PO ₄	DMA	47
12		CuO/Ag ₂ CO ₃	Brettphos	K ₃ PO ₄	DMA	53
13		CuO/Ag ₂ CO ₃	DPPE	K ₃ PO ₄	DMA	50
14		CuCl ₂ /Ag ₂ CO ₃	Phen	K ₃ PO ₄	DMA	47
15		CuBr ₂ /Ag ₂ CO ₃	Phen	K ₃ PO ₄	DMA	65
16		CuSO ₄ /Ag ₂ CO ₃	Phen	K ₃ PO ₄	DMA	60
17		CuBr ₂ /Ag ₂ CO ₃	Phen	K ₃ PO ₄	DMA	54
18		CuBr ₂ /Ag ₂ CO ₃	Phen	K ₃ PO ₄	DMA	54
19		CuCl	Phen	K ₃ PO ₄	DMA	44
20		CuBr	Phen	K ₃ PO ₄	DMA	53
21		CuI	Phen	K_3PO_4	DMA	55

22	 CuCN	Phen	K ₃ PO ₄	DMA	47
23	 CuBr ₂	Phen	K ₃ PO ₄	DMA	65
24 ^d	 CuBr ₂	Phen	K ₃ PO ₄	DMA	53
25 ^e	 CuBr ₂	Phen	K ₃ PO ₄	DMA	trace
26	 CuBr ₂		K ₃ PO ₄	DMA	75
27	 	Phen	K ₃ PO ₄	DMA	39
28	 CuBr ₂		КОН	DMA	trace
29	 CuBr ₂		Cs_2CO_3	DMA	36
30	 CuBr ₂		NaOMe	DMA	80
31	 CuBr ₂		NaOMe	DCE	40
32	 CuBr ₂		NaOMe	DMF	84

^aReaction condtions: benzoic acid **13a** (0.2 mmol), Pd catalyst (10 mol %), catalyst (20 mol %), ligand (20 mol %), base (2.0 equiv), 3 Å molecular sieves (0.4 g/mmol), solvent (1 mL), 12 h, 150 °C, O₂ atmosphere. ^bAnhydrous solvent. ^cIsolated yields. ^d Air atmosphere. ^e N₂ atmosphere.

5. General procedure for the oxidative annulation:



In a 10 mL microwave tube was charged with substrate **13a** (53.6 mg, 0.2 mmol), sodium methoxide (21.6 mg, 0.4 mmol), CuBr₂ (9.0 mg, 0.04 mmol), 3 Å molecular sieves (150 mg) and anhydrous DMF 1 mL. The reaction mixture was evacuated and refilled with O_2 for 3 times before it was stirred at 150 °C for 12 h. The reaction mixture was then cooled to rt and diluted with water (5 mL) before it was extracted with

EtOAc (30 mL). The combined organic phase were washed with water (3 X 10 mL) and saturated brine (10 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (PE/EtOAc = 3:1) on silica gel to provide the desired 3-spirooxindole benzofuranone **14a** (44.5 mg, 84%) as a white solid.

In a 50 mL microwave tube was charged with substrate **13a** (268.6 mg, 1.0 mmol), sodium methoxide (108 mg, 2.0 mmol), CuBr₂ (45 mg, 0.2 mmol), 3 Å molecular sieves (150 mg) and anhydrous DMF 5 mL. The reaction mixture was evacuated and refilled with O_2 for 3 times before it was stirred at 150 °C for 12 h. The reaction mixture was then cooled to rt and diluted with water (25 mL) before it was extracted with EtOAc (150 mL). The combined organic phase were washed with water (3 X 50 mL) and saturated brine (50 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (PE/EtOAc = 3:1) on silica gel to provide the desired 3-spirooxindole benzofuranone **14a** (209.1 mg, 79%) as a white solid.

6. Synthesis and characterization of the 3-spirooxindole benzofuranone:



1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14a):

Following the general experiment procedure, **14a** was purified by PE/EtOAc (3:1) and obtained as a white solid (44.5 mg, 84% yield); Mp = 202.5-203.5 °C; $R_f = 0.20$ (PE/EtOAc = 3:1); ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.04 (d, J = 7.4 Hz, 1 H), 7.78 (td, J = 7.4, 1.1 Hz, 1 H), 7.73 (td, J = 7.4, 0.9 Hz, 1 H), 7.54 (td, J = 7.8, 1.2 Hz, 1 H), 7.32 (d, J = 7.5 Hz, 1 H), 7.28 (d, J = 7.9 Hz, 1 H), 7.22–7.17 (m, 1 H), 7.11 (td, J = 7.5, 0.6 Hz, 1 H), 3.26 (s, 3 H) ppm; ¹³C NMR (126 MHz, DMSO-*d*₆) δ 170.6, 169.2, 146.5, 144.6, 135.5, 131.8, 130.7, 125.5, 125.0, 125.0, 124.1, 123.6, 122.3, 110.1, 84.2, 26.9 ppm; HRMS m/z (ESI) : calcd for C₁₆H₁₁NO₃ [M + H]⁺ 266.0812, found 266.0812.



1,6-dimethyl-3'H-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14b):

Following the general experiment procedure, **14b** was purified by PE/EtOAc (3:1) and obtained as a white solid (45.8 mg, 82% yield); Mp = 209.6-210.6 $^{\circ}$ C; R_f = 0.20 (PE/EtOAc = 3:1); ¹H NMR (500 MHz, CDCl₃) δ 8.01 (dd, *J* = 6.1, 2.1 Hz, 1 H), 7.64–7.60 (m, 2 H), 7.10 (dd, *J* = 5.9, 1.8 Hz, 1 H), 6.90 (s, 2 H), 6.82 (s, 1 H), 3.29 (s, 3 H), 2.44 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 171.5, 169.6, 147.0, 144.7, 142.4, 134.7, 130.2, 126.1, 126.0, 125.0, 124.3, 121.9, 121.8, 110.0, 84.5, 26.9, 22.1 ppm; HRMS m/z (ESI) calcd for C₁₇H₁₄NO₃ [M + H] ⁺ 280.0971, found 280.0968.



1,5,6-trimethyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14c):

Following the general experiment procedure, **14c** was purified by PE/EtOAc (3:1) and obtained as a white solid (39.8 mg, 68% yield); Mp = 205.1-206.1 $^{\circ}$ C; R_f = 0.22 (PE/EtOAc = 3:1); ¹H NMR (500 MHz, CDCl₃) δ 8.04–7.99 (m, 1 H), 7.66–7.56 (m, 2 H), 7.10 (dd, *J* = 5.9, 1.8 Hz, 1 H), 6.79 (d, *J* = 2.1 Hz, 2 H), 3.28 (s, 3 H), 2.35 (s, 3 H), 2.17 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 171.4, 169.7, 147.2, 142.6, 140.5, 134.7, 132.0, 130.2, 126.2, 126.1, 126.0, 121.9, 121.9, 110.6, 84.8, 27.0, 20.5, 19.3 ppm; HRMS m/z (ESI): calcd for C₁₈H₁₅NO₃ [M + H] ⁺294.1139, found 294.1125.



5-methoxy-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14d):

Following the general experiment procedure, **14d** was purified by PE/EtOAc (2:1) and obtained as a white solid (48.4 mg, 82% yield); Mp = 161-162 °C; $R_f = 0.21$ (PE/EtOAc = 2:1); ¹H NMR (500 MHz, CDCl₃) δ 8.01 (dd, J = 6.2, 1.8 Hz, 1 H), 7.65–7.59 (m, 2 H), 7.11 (dd, J = 6.2, 1.5 Hz, 1 H), 6.97 (dd, J = 8.6, 2.5 Hz, 1 H), 6.91 (d, J = 8.6 Hz, 1 H), 6.61 (d, J = 2.5 Hz, 1 H), 3.71 (s, 3 H), 3.28 (s, 3 H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 171.0, 169.6, 156.8, 147.0, 137.9, 134.9, 130.4, 126.2, 126.0, 125.9, 121.9, 116.6, 111.8, 109.8, 84.8, 55.9, 27.1 ppm; HRMS m/z (ESI) calcd for C₁₇H₁₄NO₄ [M + H] ⁺296.0911, found 296.0917.



1-methyl-5-(trifluoromethyl)-3'H-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14e):

Following the general experiment procedure, **14e** was purified by PE/EtOAc (3:1) and obtained as a white solid (44.0 mg, 66% yield). Mp = 200.1-200.8 $^{\circ}$ C; R_f = 0.25 (PE/EtOAc = 3:1); ¹H NMR (500 MHz, CDCl₃) δ 8.10–8.00 (m, 1 H), 7.75 (dd, *J* = 8.3, 0.9 Hz, 1 H), 7.71–7.62 (m, 2 H), 7.27 (d, *J* = 1.9 Hz, 1 H), 7.19–7.04 (m, 2 H), 3.35 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 171.2 (s), 169.0 (s), 147.6 (s), 145.9 (s), 135.1 (s), 130.8 (s), 129.4 (q, *J* = 3.9 Hz),

126.4 (s), 126.1 (s), 125.8 (s), 125.6 (s), 123.7 (d, J = 271.9 Hz), 122.4 (q, J = 3.7 Hz), 121.8 (s), 109.2 (s), 83.5 (s), 27.3 (s) ppm; HRMS m/z (ESI): calcd for C₁₇H₁₀F₃NO₃ [M + H] + 334.0690, found 334.0686.



5-fluoro-1-methyl-3'H-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14f):

Following the general experiment procedure, **14f** was purified by PE/EtOAc (3:1) and obtained as a white solid (48.1 mg, 85% yield); $R_f = 0.24$ (PE/EtOAc = 3:1); Mp = 193-194 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.67 (dd, J = 7.0, 2.3 Hz, 1 H), 7.48 (td, J = 7.8, 1.3 Hz, 1 H), 7.35 (td, J = 8.5, 2.4 Hz, 1 H), 7.13–7.10 (m, 1 H), 7.09 (t, J = 4.2 Hz, 1 H), 7.04 (dd, J = 7.5, 0.9 Hz, 1 H), 7.01 (d, J = 7.9 Hz, 1 H), 3.31 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 171.0 (s), 169.2 (s), 160.5 (s), 158.6 (s), 146.3 (s), 140.5 (d, J = 2.2 Hz), 134.9 (s), 130.6 (s), 126.3 (d, J = 9.5 Hz), 125.7 (s), 121.8 (s), 118.1 (d, J = 23.6 Hz), 113.3 (d, J = 25.3 Hz), 101.0 (d, J = 7.9 Hz), 84.1 (s), 27.2 (s) ppm; HRMS m/z (ESI) calcd for C₁₆H₁₀FNO₃ [M + H] + 284.0720, found 284.0717.



5-chloro-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14g):

Following the general experiment procedure, 14g was purified by PE/EtOAc (3:1) and obtained as a white solid (47.8 mg, 80% yield); Mp = 177-178 °C;

 $R_f = 0.23$ (PE/EtOAc = 3:1); ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.05–8.02 (m, 1 H), 7.78 (td, *J* = 7.5, 1.3 Hz, 1 H), 7.74 (td, *J* = 7.4, 1.1 Hz, 1 H), 7.61 (dd, *J* = 8.4, 2.2 Hz, 1 H), 7.46 (d, *J* = 2.2 Hz, 1 H), 7.36 (dd, *J* = 4.6, 3.7 Hz, 1 H), 7.31 (d, *J* = 8.5 Hz, 1 H), 3.26 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 170.8, 169.1, 146.2, 143.2, 135.0, 131.6, 130.7, 129.2, 126.4, 126.3, 125.7, 125.6, 121.8, 110.3, 83.9, 27.2 ppm; HRMS m/z (ESI) calcd for C₁₆H₁₀ClNO₃ [M + H]⁺ 322.0246, found 322.0241.



5-fluoro-1-isopropyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14h):

Following the general experiment procedure, **14h** was purified by PE/EtOAc (3:1) and obtained as a white solid (50.4 mg, 81% yield). Mp = 132-133 °C; $R_f = 0.24$ (PE/EtOAc = 3:1); ¹H NMR (500 MHz, CDCl₃) δ 8.03 (dd, J = 6.3, 1.7 Hz, 1 H), 7.64 (pd, J = 7.4, 1.3 Hz, 2 H), 7.13 (td, J = 8.7, 2.6 Hz, 1 H), 7.10–7.06 (m, 2 H), 6.78 (dd, J = 7.2, 2.6 Hz, 1 H), 4.59 (dt, J = 14.0, 7.0 Hz, 1 H), 1.57–1.53 (m, 6 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 170.6 (s), 169.3 (s), 159.2 (d, J = 243.9 Hz), 146.6 (s), 139.3 (s), 134.9 (s), 130.5 (s), 127.0 (d, J = 7.8 Hz), 126.3 (s), 125.7 (s), 121.5 (s), 117.8 (d, J = 23.3 Hz), 113.5 (d, J = 25.0 Hz), 111.5 (d, J = 7.7 Hz), 84.0 (s), 45.2 (s), 19.1 (s) ppm; HRMS m/z (ESI) : calcd for C₁₈H₁₅FNO₃ [M + H]⁺ 312.1043, found 312.103.



5-chloro-1-isopropyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14i):

Following the general experiment procedure, **14i** was purified by PE/EtOAc (3:1) and obtained as a white solid (40.0 mg, 61% yield); Mp = 158.7-159.8 $^{\circ}$ C; R_f = 0.25 (PE/EtOAc = 3:1); ¹H NMR (500 MHz, CDCl₃) δ 8.05–8.02 (m, 1 H), 7.65 (pd, *J* = 7.4, 1.3 Hz, 2 H), 7.40 (dd, *J* = 8.5, 2.2 Hz, 1 H), 7.09 (dd, *J* = 10.1, 4.9 Hz, 2 H), 7.01 (d, *J* = 2.2 Hz, 1 H), 4.59 (dt, *J* = 14.0, 7.0 Hz, 1 H), 1.55 (t, *J* = 7.3 Hz, 6 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 170.4, 169.2, 146.5, 141.9, 135.0, 131.3, 130.6, 128.8, 127.0, 126.3, 125.9, 125.7, 121.5, 111.7, 83.8, 45.3, 19.5, 19.1 ppm; HRMS m/z (ESI): calcd for C₁₈ H₁₅ClNO₃ [M + H] + 328.0728, found 328.0735.



1-benzyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14j):

Following the general experiment procedure, **14j** was purified by PE/EtOAc (3:1) and obtained as a white solid (55.2 mg, 81% yield). Mp = 163.5-164.5 $^{\circ}$ C; R_f= 0.23 (PE/EtOAc = 3:1); ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.07 (d, *J* = 7.5 Hz, 1 H), δ 7.84–7.79 (m, 1 H), 7.76 (t, *J* = 7.4 Hz, 1 H), 7.46 (td, *J* = 7.9, 1.0 Hz, 1 H), 7.43–7.30 (m, 5 H), 7.29 (d, *J* = 7.5 Hz, 1 H), 7.24 (d, *J* = 7.3 Hz, 1 H), 7.21 (d, *J* = 7.9 Hz, 1 H), 7.09 (t, *J* = 7.5 Hz, 1 H), 5.02 (d, *J* = 3.3 Hz, 2 H) ppm; ¹³C NMR (126 MHz, DMSO-*d*₆) δ 170.9, 169.1, 146.4, 143.5, 135.7, 135.6, 131.8, 130.8, 128.9, 127.7, 127.2, 125.7, 125.4, 125.0, 124.1, 123.8, 122.1, 110.7, 84.1, 43.5 ppm; HRMS m/z (ESI) : calcd for C₂₂H₁₅NO₃ [M + H]⁺ 342.1128, found 342.1125.



1-isopropyl-5-methyl-3'H-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14k):

Following the general experiment procedure, **14k** was purified by PE/EtOAc (3:1) and obtained as a white solid (52.8 mg, 86% yield); Mp = 171.8-172.7 $^{\circ}$ C; R_f = 0.21 (PE/EtOAc = 3:1); ¹H NMR (500 MHz, CDCl₃) δ 8.03–8.00 (m, 1 H), 7.62 (pd, *J* = 7.4, 1.3 Hz, 2 H), 7.25–7.18 (m, 1 H), 7.11–7.07 (m, 1 H), 7.03 (d, *J* = 8.1 Hz, 1 H), 6.87–6.81 (m, 1 H), 4.63–4.54 (m, 1 H), 2.26 (s, 3 H), 1.55 (dd, *J* = 8.7, 7.0 Hz, 6 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 170.7, 169.7, 147.3, 140.9, 134.7, 133.0, 131.6, 130.2, 126.1, 126.0, 125.9, 125.3, 121.6, 110.5, 84.6, 45.0, 20.8, 19.6, 19.2 ppm; HRMS m/z (ESI): calcd for C₁₉H₁₈NO₃ [M + H] ⁺ 308.1283, found 308.1281.



1,5'-dimethyl-3'H-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16a):

Following the general experiment procedure, **16a** was purified by PE/EtOAc (3:1) and obtained as a white solid (34.6 mg, 62% yield); Mp =218.7-219.4 $^{\circ}$ C; R_f = 0.21 (PE/EtOAc = 3:1); ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.84 (s, 1 H), 7.58 (dd, *J* = 7.9, 0.7 Hz, 1 H), 7.53 (td, *J* = 7.8, 1.3 Hz, 1 H), 7.27 (d, *J* = 7.9 Hz, 1 H), 7.19 (d, *J* = 7.9 Hz, 1 H), 7.16 (dd, *J* = 7.4, 0.9 Hz, 1 H), 7.10 (td, *J* = 7.5, 0.7 Hz, 1 H), 3.25 (s, 3 H), 2.46 (s, 3 H) ppm; ¹³C NMR (126 MHz, 126 MH

CDCl₃) δ 171.4, 169.7, 144.6, 144.2, 140.9, 135.9, 131.6, 126.2, 126.1, 125.2, 125.0, 123.7, 121.5, 109.1, 84.3, 27.0, 21.3 ppm; HRMS m/z (ESI): calcd for C₁₇H₁₄NO₃ [M + H] ⁺ 280.0966, found 280.0968.



6'-methoxy-1-methyl-3'H-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16b):

Following the general experiment procedure, **16b** was purified by PE/EtOAc (2:1) and obtained as a white solid (45.4 mg, 77% yield); Mp = 187.5-188.5 $^{\circ}$ C; R_f = 0.21 (PE/EtOAc = 2:1); ¹H NMR (500 MHz, CDCl₃) δ 7.90 (d, *J* = 8.5 Hz, 1 H), 7.46 (td, *J* = 7.8, 1.2 Hz, 1 H), 7.14–7.07 (m, 2 H), 7.04 (dd, *J* = 7.4, 0.8 Hz, 1 H), 7.00 (d, *J* = 7.9 Hz, 1 H), 6.47 (d, *J* = 2.0 Hz, 1 H), 3.80 (s, 3 H), 3.31 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 171.3, 169.2, 165.26, 149.5, 144.6, 131.6, 127.5, 125.2, 125.0, 123.8, 118.2, 117.9, 109.1, 105.6, 83.8, 55.9, 27.0 ppm; HRMS m/z (ESI) : calcd for C₁₇H₁₃NO₄ [M + H] ⁺ 296.0920, found 296.0917.



5'-fluoro-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16c):

Following the general experiment procedure, **16c** was purified by PE/EtOAc (3:1) and obtained as a white solid (37.4 mg, 66% yield); Mp = 193-194 °C; $R_f = 0.23$ (PE/EtOAc = 3:1); ¹H NMR (500 MHz, CDCl₃) δ 7.89–7.87 (m, 1 H), 7.75 (dd, J = 8.2, 1.6 Hz, 1 H), 7.49 (td, J = 7.8, 1.3 Hz, 1 H), 7.26–7.26 (m, 1 H), 7.12 (td, J = 7.6, 0.9 Hz, 1 H), 7.05 (dd, J = 7.5, 0.8 Hz, 1 H), 7.02 (d, J = 7.9 Hz, 1 H), 3.32 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 169.5 (d, J = 322.9 Hz), 163.8 (d, J = 251.5 Hz), 144.6 (s), 142.3 (d, J = 2.3 Hz), 131.9 (s), 128.3 (d, J = 9.3 Hz), 125.2 (s), 124.3 (s), 123.8 (d, J = 8.8 Hz), 122.8 (d, J = 24.3 Hz), 112.6 (s), 112.4 (s), 109.3 (s), 84.3 (s), 27.0 (s) ppm; HRMS m/z (ESI) calcd for C₁₆H₁₀FNO₃ [M + H] ⁺284.0720, found 284.0717.



6'-chloro-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16d):

Following the general experiment procedure, **16d** was purified by PE/EtOAc (3:1) and obtained as a white solid (38.3 mg, 64% yield); Mp = 203.5-204.5 $^{\circ}$ C; R_f = 0.23 (PE/EtOAc = 3:1); ¹H NMR (500 MHz, CDCl₃) δ 7.95 (d, *J* = 8.1 Hz, 1 H), 7.59 (dd, *J* = 8.2, 1.7 Hz, 1 H), 7.49 (td, *J* = 7.8, 1.3 Hz, 1 H), 7.12 (td, *J* = 7.6, 0.8 Hz, 1 H), 7.09 (d, *J* = 1.4 Hz, 1 H), 7.05 (dd, *J* = 7.4, 0.9 Hz, 1 H), 7.02 (d, *J* = 7.9 Hz, 1 H), 3.32 (s, 3 H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 170.6, 168.3, 148.3, 144.6, 141.5, 132.0, 131.1, 127.2, 125.2, 124.5, 124.1, 124.0, 122.3, 109.3, 83.9, 27.1 ppm; HRMS m/z (ESI) : calcd for C₁₆H₁₀ClNO₃ [M + H] ⁺ 300.0424, found 300.0422.



6'-bromo-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16e):

Following the general experiment procedure, **16e** was purified by PE/EtOAc (3:1) and obtained as a white solid (45.3 mg, 66% yield); Mp = 224.8-225.8 $^{\circ}$ C; R_f = 0.21 (PE/EtOAc = 3:1); ¹H NMR (500 MHz, CDCl₃) δ 7.67 (dd, *J* = 7.0, 2.3 Hz, 1 H), 7.48 (td, *J* = 7.8, 1.3 Hz, 1 H), 7.35 (td, *J* = 8.5, 2.4 Hz, 1 H), 7.14–7.11 (m, 1 H), 7.09 (t, *J* = 4.2 Hz, 1 H), 7.04 (dd, *J* = 7.5, 0.9 Hz, 1 H), 7.01 (d, *J* = 7.9 Hz, 1 H), 3.31 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 170.6, 168.5, 148.4, 144.6, 134.0, 132.0, 130.0, 127.3, 125.3, 125.0, 124.1, 124.0, 109.3, 83.9, 27.1 ppm; HRMS m/z (ESI): calcd for C₁₆H₁₀BrNO₃ [M + H] ⁺ 343.9923, found 343.9917.



5-methoxy-1,5'-dimethyl-3'H-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16f):

Following the general experiment procedure, **16f** was purified by PE/EtOAc (2:1) and obtained as a white solid (40.2 mg, 65% yield); Mp = 145.5-146.5 °C; $R_f = 0.20$ (PE/EtOAc = 2:1); ¹H NMR (500 MHz, CDCl₃) δ 7.81 (s, 1 H), 7.46–7.43 (m, 1 H), 7.00 (d, J = 7.9 Hz, 1 H), 6.97 (dd, J = 8.6, 2.5 Hz, 1 H), 6.90 (d, J = 8.6 Hz, 1 H), 6.61 (d, J = 2.5 Hz, 1 H), 3.72 (s, 3 H), 3.28 (s, 3 H), 2.49 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 171.1, 169.7, 156.7, 144.3,

140.9, 137.8, 135.9, 126.1, 126.1, 121.5, 116.5, 111.7, 109.7, 84.6, 55.9, 27.0, 21.4 ppm; HRMS m/z (ESI): calcd for $C_{18}H_{16}NO_4$ [M + H] ⁺ 310.1081, found 310.1074.



5-chloro-1,5'-dimethyl-3'H-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16g):

Following the general experiment procedure, **16g** was purified by PE/EtOAc (3:1) and obtained as a white solid (34.4 mg, 55% yield); Mp = 216.5-217.5 $^{\circ}$ C; R_f = 0.20 (PE/EtOAc = 2:1); ¹H NMR (500 MHz, CDCl₃) δ 7.84–7.80 (m, 1 H), 7.47 (dd, *J* = 7.9, 0.8 Hz, 1 H), 7.43 (dd, *J* = 8.4, 2.1 Hz, 1 H), 7.03–6.97 (m, 2 H), 6.93 (d, *J* = 8.4 Hz, 1 H), 3.30 (s, 3 H), 2.50 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 171.0, 169.3, 143.6, 143.1, 141.2, 136.1, 131.5, 129.2, 126.6, 126.2, 126.0, 125.5, 121.5, 110.2, 83.8, 27.1, 21.3 ppm; HRMS m/z (ESI) calcd for C₁₇H₁₂ClNO₃ [M + H] ⁺ 314.0581, found 314.0578.



5-chloro-6'-methoxy-1-methyl-3'H-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16h):

Following the general experiment procedure, **16h** was purified by PE/EtOAc (2:1) and obtained as a white solid (46.1 mg, 70% yield); Mp = 234-235 °C; $R_f = 0.2$ (PE/EtOAc = 2:1); ¹H NMR (500 MHz, CDCl₃) δ 7.91 (d, J = 8.5 Hz, 1 H), 7.43 (dd, J = 8.3, 2.0 Hz, 1 H), 7.12 (dd, J = 8.6, 2.0 Hz, 1 H), 7.03 (d, J = 2.0 Hz, 1 H), 6.94 (d, J = 8.4 Hz, 1 H), 6.48 (d, J = 1.9 Hz, 1 H), 3.82 (s, 3 H), 3.30 (s, 3 H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ 170.9, 168.8, 165.4, 148.9,

143.1, 131.5, 129.3, 127.8, 126.7, 125.7, 118.0, 118.0, 110.2, 105.7, 83.3, 56.0, 27.2 ppm; HRMS m/z (ESI): calcd for C₁₇H₁₂ClNO₄ [M + H] ⁺ 330.0529, found 330.0528.



5,6'-dichloro-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16i):

Following the general experiment procedure, **16i** was purified by PE/EtOAc (3:1) and obtained as a white solid (41.4 mg, 62% yield); $R_f = 0.21$ (PE/EtOAc = 3:1); Mp = 238.9-239.9 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.96 (d, J = 8.2 Hz, 1 H), 7.61 (dd, J = 8.2, 1.7 Hz, 1 H), 7.46 (dd, J = 8.4, 2.1 Hz, 1 H), 7.10 (d, J = 1.3 Hz, 1 H), 7.04 (d, J = 2.1 Hz, 1 H), 6.96 (d, J = 8.4 Hz, 1 H), 3.31 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 170.2, 167.9, 147.7, 143.1, 141.8, 131.9, 131.4, 129.5, 127.4, 125.7, 124.3, 122.3, 110.4, 83.3, 27.2 ppm; HRMS m/z (ESI): calcd for C₁₆H₉Cl₂NO₃ [M + H] ⁺ 334.0034, found 334.0032.

7. The data of crystal:

F N Me			
16c = 1			
Compound	16c = 1		
Formula	C16 H10 F N O3		
Mr	283.25		
Crystal system	monoclinic		
Space group	P2(1)/c		
a/Å	10.8437(15)		
b/Å	16.386(2)		
c/Å	7.5183(10)		
$\alpha/^{\circ}$	90		
$eta / ^{\circ}$	100.479(15)		

_		
	$\gamma/^{\circ}$	90
	$V/\text{\AA}^3$	1313.6(3)
	Ζ	4
	$D_{\rm calcd}$ /g·cm ⁻³	1.432
	μ /mm ⁻¹	0.109
	No. of data/parameter	2578/190
	θ range/°	3.02-26.00
	Obs reflns	1702
	$R_1 \left[I > 2\sigma(I)\right]^a$	0.0491
	wR_2 (all data) ^b	0.1226

 ${}^{a}R_{1} = \sum ||F_{O}| - |F_{C}|| / \sum |F_{O}| \qquad {}^{b}wR_{2} = \{\sum [w(F_{O}{}^{2} - F_{C}{}^{2})^{2}] / \sum [w(F_{O}{}^{2})^{2}] \}^{1/2}$

8. Experiments about mechanistic studies:



In a 25 mL microwave tube was charged with substrate **13a** (132.5.0 mg, 0.5 mmol), sodium methoxide (54 mg, 1.0 mmol), CuBr₂ (22.5 mg, 0.1 mmol), 3 Å molecular sieves (150 mg) and anhydrous DMF 10 mL. The reaction mixture was evacuated and refilled with O_2 for 3 times before it was stirred at 90 °C for 28 h. The reaction mixture was then cooled to rt and diluted with water (5 mL) before it was extracted with EtOAc (30 mL). The combined organic phase were washed with and washed with water (3 X 10 mL) and saturated brine (10 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The

residue was purified by column chromatography (PE/EtOAc=3:1) on silica gel to provide the products 17 (12.6 mg, 10%), 18 (34.5 mg, 26%) and 14a (39.8 mg, 30%). Substrate 13a (35.2 g, 28%) was recovered.

3-(2-(methylamino)phenyl)-1H-isochromen-1-one (17)

The NMR data are consistent with those reported:¹ Mp = 155.8-156.7 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.34–8.28 (m, 1 H), 7.77–7.70 (m, 1 H), 7.54–7.49 (m, 1 H), 7.48 (d, *J* = 7.9 Hz, 1 H), 7.43 (dd, *J* = 7.7, 1.6 Hz, 1 H), 7.39–7.32 (m, 1 H), 6.77 (tt, *J* = 4.0, 2.0 Hz, 1 H), 6.74 (t, *J* = 4.1 Hz, 2 H), 5.12 (s, 1 H), 2.91 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 162.4, 155.4, 147.3, 137.8, 134.9, 131.5, 129.6, 129.5, 128.0, 125.8, 120.0, 117.6, 116.7, 111.0, 104.9, 30.6 ppm.

1-methyl-3'H-spiro[indoline-2,1'-isobenzofuran]-3,3'-dione (18)

The NMR data are consistent with those reported:¹ Mp = 212-213 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.05–7.99 (m, 1 H), 7.66 (dtdd, *J* = 15.5, 9.5, 7.4, 1.3 Hz, 4 H), 7.34–7.29 (m, 1 H), 6.95–6.90 (m, 1 H), 6.88 (d, *J* = 8.2 Hz, 1 H), 2.76 (s, 3 H) ppm; ¹³C NMR (126 MHz, CDCl₃) δ 192.9, 168.2, 161.2, 142.3, 139.0, 134.8, 131.2, 128.6, 126.1, 126.0, 122.3, 119.6, 118.3, 109.0, 96.6, 27.8 ppm.



In a 10 mL microwave tube was charged with substrate 17 (50.2 mg, 0.2 mmol), sodium methoxide (10.8 mg, 0.4 mmol), CuBr₂ (9.0 mg, 0.04 mmol), 3 Å molecular sieves (150 mg) and anhydrous DMF 1.0 mL. The reaction mixture was evacuated and refilled with O_2 for 3 times before it was stirred at 150 °C for 12 h. The reaction mixture was then cooled to rt and diluted with water (5 mL) before it was extracted with EtOAc (30 mL). The combined organic phase were washed with and washed with water (3 X 10 mL) and saturated brine (10 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (PE/EtOAc=3:1) on silica gel to provide the products 14a (40.3 mg, 76%).



In a 10 mL microwave tube was charged with substrate **18** (55.8 mg, 0.2 mmol), sodium methoxide (10.8 mg, 0.4 mmol), CuBr₂ (9.0 mg, 0.04 mmol), 3 Å molecular sieves (150 mg) and anhydrous DMF 1.0 mL. The reaction mixture was evacuated and refilled with O_2 for 3 times before it was stirred at 150 °C for 12 h. The reaction mixture was then cooled to rt and diluted with water (5 mL) before it was extracted with EtOAc (30 mL). The combined organic phase were washed with and washed with water (3 X 10 mL) and saturated brine (10 mL), dried over anhydrous magnesium sulfate and concentrated *in vacuo*. The residue was purified by column chromatography (PE/EtOAc=3:1) on silica gel to provide the products **14a** (39.8 mg, 75%).

9. References:

- 1. R. M. Letcher, N.-C. Kwok, W.-H. Lo, K.-W. Ng, J. Chem. Soc., Perkin Trans. 1, 1998, 1715.
- 2. (a) D. A. Offermann, J. E. McKendrick, J. J. P. Sejberg, A. C. Spivey, J. Org. Chem. 2012, 77, 3197. (b) M. Hellal, J. -J. Bourguignon, F. J.-J. Bihel, Tetrahedron Lett., 2008, 49, 62.

10. NMR spectra of all new compounds:



2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13a):




2-(2-(4-methyl-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13b):





2-(2-(4,5-dimethyl-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13c):





2-(2-(5-methoxy-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13d):





2-(2-(2-(methylamino)-5-(trifluoromethyl)phenyl)-2-oxoethyl)benzoic acid (13e):



2-(2-(5-fluoro-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13f):







2-(2-(5-chloro-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (13g):





2-(2-(5-fluoro-2-(isopropylamino)phenyl)-2-oxoethyl)benzoic acid (13h):



2-(2-(5-chloro-2-(isopropylamino)phenyl)-2-oxoethyl)benzoic acid (13i):





S53

2-(2-(2-(benzylamino)phenyl)-2-oxoethyl)benzoic acid (13j):







2-(2-(isopropylamino)-5-methylphenyl)-2-oxoethyl)benzoic acid (13k):



5-methyl-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15a):





- 4.75 có có m m m m m ${\bf \overrightarrow{\ }} \stackrel{}{\mapsto} \stackrel{}{\mapsto} \stackrel{}{\mapsto} \stackrel{}{\cup} \stackrel{}{$ -45000 8.03 8.01 8.01 7.95 7.95 7.93 $\sum_{\substack{7.44\\7.44}}^{7.44}$ -12000 -40000 0 COOH -10000 Ľ ſ. -35000 8000 ÓMe Me 6000 15b -30000 -4000 -2000 -25000 -0 27 9.8 8 8 20000 8.6 8.4 8.2 8.0 7.8 7.6 7.4 7.2 7.0 6.8 6.6 6.4 6.2 fl (ppm) -15000 -10000 -5000 J⊢0 2. 01.T 3.06. 1.00 1.00 1.1 3. 09-I 0.98-I 1. 00**H** 2 6 13.0 12.5 12.0 11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 f1 (ppm)

4-methoxy-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15b):



S61

5-fluoro-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15c):







4-chloro-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15d):





4-bromo-2-(2-(2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15e):





2-(2-(5-methoxy-2-(methylamino)phenyl)-2-oxoethyl)-5-methylbenzoic acid (15f):





2-(2-(5-chloro-2-(methylamino)phenyl)-2-oxoethyl)-5-methylbenzoic acid (15g):





2-(2-(5-chloro-2-(methylamino)phenyl)-2-oxoethyl)-4-methoxybenzoic acid (15h):




4-chloro-2-(2-(5-chloro-2-(methylamino)phenyl)-2-oxoethyl)benzoic acid (15i):



S75

1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione(14a):













1,5,6-trimethyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14c):





5-methoxy-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14d):





1-methyl-5-(trifluoromethyl)-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14e):





5-fluoro-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14f):





5-chloro-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14g):





5-fluoro-1-isopropyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14h):





5-chloro-1-isopropyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14i):





1-benzyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14j):





1-isopropyl-5-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (14k):





1,5'-dimethyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16a):





6'-methoxy-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16b):





5'-fluoro-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16c):





6'-chloro-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16d):



6'-bromo-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16e):







5-methoxy-1,5'-dimethyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16f):




5-chloro-1,5'-dimethyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)]-2,3'-dione (16g):





5-chloro-6'-methoxy-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16h):



S113



5,6'-dichloro-1-methyl-3'*H*-spiro(indoline-3,1'-isobenzofuran)-2,3'-dione (16i):



S115



3-(2-(methylamino)phenyl)-1*H*-isochromen-1-one (17):





1-methyl-3'*H*-spiro[indoline-2,1'-isobenzofuran]-3,3'-dione (18):

